Granulocyte colony-stimulating factor: Its potential role in infectious disease

AIDS, Supplement

Volumn 13, Issue 2, 1999, Pages

  Hartung, Thomas ^a  

^a UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

Antibiotics; Granulocyte colony stimulating factor; HIV; Immunomodulation; Infectious disease; Neutrophil; Recombinant methionyl human granulocyte colony stimulating factor

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

CONFERENCE PAPER; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INFECTIOUS COMPLICATION; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADJUVANTS, IMMUNOLOGIC; ANTI-BACTERIAL AGENTS; COMMUNICABLE DISEASES; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HIV-1; HUMANS; NEUTROPENIA; NEUTROPHILS;

EID: 0032803384     PISSN: 13502840     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (67)

1. Hollingshead LM, Goa KL. Recombinant granulocyte colony-stimulating factor (rG-CSF): a review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 1991, 42:300-330.
2. Kapp A, Zeck-Kapp G. Activation of the oxidative metabolism in human polymorphonuclear neutrophilic granulocytes: the role of immuno-modulating cytokines. J Invest Dermatol 1990, 95:945-95.
3. Layton JE. Granulocyte colony-stimulating factor: structure, function and physiology. Growth Factors 1992, 6:179-186.
4. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996, 6:1907-1929.
5. De Arriba F, Lozano ML, Ortuno F, Heras I, Moraleda JM, Vicente V. Prospective randomized study comparing the efficacy of bioequivalent doses of glycosylated and nonglycosylated rG-CSF for mobilizing peripheral blood progenitor cells. Br J Haematol 1997, 96:418-420.
6. Conlan JW. Critical roles of neutrophils in host defense against experimental systemic infections of mice by Listeria monocytogenes, Salmonella typhimurium, and Yersinia enterocolitica. Infect Immun 1997, 65:630-635.
7. Lieschke GJ, Grail D, Hodgson G, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994, 84:1737-1746.
8. Cebon J, Layton JE, Maher D, Morstyn G. Endogenous haematopoietic growth factors in neutropenia and infection. Br J Haematol 1994, 86:265-274.
9. Morstyn G, Foote M, Nelson S. Clinical benefits of improving host defences with rHuG-CSF. Ciba Found Symp 1997, 204:78-87.
10. Roilides F, Pizzo PA. Perspectives on the use of cytokines in the management of infectious complications of cancer. Clin Infect Dis 1993, 17(suppl 2);385-389.
11. Uchiyama H, Shimazaki C, Fujita N, et al. Kinetics of serum cytokines in adults undergoing peripheral blood progenitor cell transplantation. Br J Haematol 1994, 88:639-642.
12. Hermans P, Rozenbaum W, Jou A, et al. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. G-CSF 92105 study group. AIDS 1996, 10:1627-1633.
13. Moses AV, Williams S, Heneveld ML, et al. Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors. Blood 1996, 87:919-925.
14. Mauss S, Steinmetz HT, Willers R, et al. Induction of granulocyte colony-stimulating factor by acute febrile infection but not by neutropenia in HIV-seropositive individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:430-434.
15. Barsig J, Bundschuh DS, Hartung T, Bauhofer A, Sauer A, Wendel A. Control of fecal peritoneal infection in mice by colony-stimulating factors. J Infect Dis 1996, 174:790-799.
16. Waring PM, Presneill J, Maher DW, et al. Differential alterations in plasma colony-stimulating factor concentrations in meningococcaemia. Clin Exp Immunol 1995, 102:501-506.
17. Kragsjberg P, Jones I, Vikerfors T, Holmberg H. Diagnostic value of blood cytokine concentrations in acute pneumonia Thorax 1995, 50:1253-1257.
18. Tanaka H, Ishikawa K, Nishino M, Shimazu T, Yoshioka T. Changes in granulocyte colony-stimulating factor concentration in patients with trauma and sepsis. J Trauma 1996, 40:718-726.
19. Metcalf D. Control of granulocytes and macrophages: molecular, cellular, and clinical aspects. Science 1991, 254: 529-533.
20. Frampton JE, Rhonda Lee C, Faulds D. Filgrastim: a review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 1994, 48:731-760.
21. Avalos BR. Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood 1996, 88:761-777.
22. Vollmer K, Mandell GL. Effect of colony-stimulating factors on granulocyle function. Recent Results Cancer Res 1993, 132:103-108.
23. Roilides E, Walsh TJ, Pizzo PA, Rubin M. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 1991, 163:579-583.
24. Allen RC, Stevens PR, Price TH, Chatta GS, Dale DC. In vivo effects of recombinant granulocyte colony-stimulating factor on neutrophil oxidative functions in normal human volunteers. J Infect Dis 1997, 175:1194-1192.
25. Hoyd AR, Biragyn A, Johnston JA, et al. Granulocyte colony-stimulating factor and lipopolysaccharide regulate the expression of interleukin 8 receptors on polymorphonuclear leukocytes. J Biol Chem 1995, 270:88-92.
26. Káposzla R, Maródi L. Chronic neutropenia and defect in superoxide generation of granulocytes in two patients: enhancement of bactericidal capacity and respiratory burst activity by treatment with recombinant human granulocyte colony-stimulating factor. Pediatr Res 1995, 37:50-55.
27. Hartung T, von Aulock S, Wendel A. Role of granulocyte colony-stimulating factor (G-CSF) in infection and inflammation. Med Microbiol Immunol 1998, 187:61-69.
28. Hartung T, Döcke WD, Gantner F, et al. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 1995; 85:2482-2489.
29. Repp R, Valerius I, Sendler A, et al. Neutrophils express the high affinity receptor for IgC (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor. Blood 1991, 78:885-889.
30. Ohsaka A, Saionji K, Kuwaki I, Takeshima T, Igari J. Granulocyte colony-stimulating factor modulates the surface expression of effector cell molecules on human monocytes. Br J Haematol 1995, 89:465-472.
31. Pajkrt D, Manten A, van der Poll T, et al. Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. Blood 1997, 90:1415-1424.
32. Bussolino F, Colotta F, Bocchietto E, Guglielmetti A, Mantovani A. Recent developments in the cell biology of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor: activities on endothelial cells. Int J Clin Lab Res 1995, 23:8-12.
33. O'Reilly M, Silver GM, Greenhalgh DG, Gamelli RL, Davis JH, Hebert JC. Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. J Trauma 1992, 33:679-682.
34. Goya T, Torisu M, Doi F, Yoshida T. Effects of granulocyte colony-stimulating factor and monobactam antibiotics (Aztreonam) on neutrophil functions in sepsis. Clin Immunol Immunopathol 1993, 69:278-284.
35. Toda H, Murata A, Matsuura N, et al. Therapeutic efficacy of granulocyte colony-stimulating factor against rat cecal ligation and puncture model. Stem Cells 1993, 11:228-234.
36. Serushago BA, Yoshikai Y, Handa T, Mitsuyama M, Muramori K, Nomoto K. Effect of recombinant granulocyte colony-stimulating factor (rhG-CSF) on murine resistance against Listeria monocytogenes. Immunology 1992, 75:475-480.
37. Lister PD, Gentry MJ, Preheim LC. Granulocyte colony-stimulating factor protects control rats but not ethanol-fed rats from fatal pneumococcal pneumonia. J Infect Dis 1993, 168: 922-926.
38. Nelson S, Summer W, Bagby G, et al. Granulocyte colony-stimulating factor enhances pulmonary host defenses in normal and ethanol-treated rats. J Infect Dis 1991, 164:901-906.
39. Mooney DP, Gamelli RL, O'Reilly M, Hebert JC. Recombinant human granulocyte colony-stimulating factor and Pscudomonas burn wound sepsis. Arch Surg 1988, 123:1353-1357.
40. Silver CM, Gamelli RL, O'Reilly M. The beneficial effect of granulocyte colony-stimulating factor (G-CSF) in combination with gentamycin on survival after pseudomonas burn wound infection. Surgery 1989, 106:452-456.
41. Sartorelli KH, Silver GM, Gamelli RI. The effect of granulocyte colony-stimulating factor (G-CSF) upon burn-induced defective neutrophil chemotaxis. J Trauma 1991, 31:523-530.
42. Yasuda H, Ajiki Y, Shimozato I, et al. Therapeutic efficacy of granulocyte colony-stimulating factor alone and in combination with antibiotics against pseudomonas aeruginosa infections in mice. Infect Immun 1990, 58:2502-2509.
43. Lorenz W, Reimund KP, Weitzel F, et al. Granulocyte colony-stimulating factor prophylaxis before operation protects against lethal consequences of postoperative peritonitis. ,Surgery 1994, 116:925-934.
44. Kropec A, Lemmen SW, Grundmann HJ, Engels I, Daschner FD. Synergy of simultaneous administration of ofloxacin and granulocyte colony-stimulating factor in killing of Escherichia coli by human neutrophils. Infection 1995, 23:298-300.
45. McKenna PJ, Nelson S, Andresen J. Filgrastim (rHuG-tSF) enhances ciprofloxacin uptake and bactericidal activity of human neutrophils in vitro [abstract 535]. Am J Respir Crit Care Med 1996, 153.
46. Dale DC. Hematopoietic growth factors for the treatment of severe chronic neutropenia. Stem Cells (Dayt) 1995, 2:94-100.
47. Hoelzer D. Hematopoietic growth factor - not whether, but when and where. N Eng J Med 1997, 336:1922-1824.
48. Frumkin LR. Role of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the treatment of patients with HIV infection. Curr Opin Hematol 1997, 4:200-206.
49. Slobod KS, Bennett TA, Freiden PJ, et al. Mobilization of CD34+ progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type 1-infected adults. Blood 1996, 88:3329-3335.
50. Nielsen SD, Dam-Larsen S, Nielsen C, Wantzin P, Mathiesen L, Hanson J-ES. Recombinant human granulocyte colony-stimulating factor increases circulating CD34-positive cells in patients with AIDS. Ann Hematol 1997, 74:215-220.
51. Stricker RB, Goldberg B. Increase in lymphocyte subsets following treatment of HIV-associated neutropenia with granulocyte colony-stimulating factor. Clin Immunol Immunopathol 1996, 79:194-196.
52. Ieki R, Furuta T, Asano S, et al. Effect of recombinant human granulocyte colony-stimulating factor on Pneumocystis carinii infection in nude mice. Am J Resp Crit Care Med 1989, 59:51-58.
53. Lazard T, Perronne C, Cohen Y, Grosset J, Vilde J-L, Pocidalo J-J. Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in CB57BL/6 mice. Antimicrob Agents Chemother 1993, 37:692-695.
54. Futenma M, Kawakami K, Saito A. Production of tumor necrosis factor-α in granulocytopenic mice with pulmonary candidiasis and its modification with granulocyte colony-stimulating factor. Microbiol Immunol 1995, 39:411-417.
55. Preheim LC, Snitily MU, Gentry MJ. Effects of granulocyte colony-stimulating factor in cirrhotic rats with pneumococcal pneumonia. J Infect Dis 1996, 174:225-228.
56. Roilides E, Holmes A, Blake C, Pizzo PA, Walsh TJ. Effects of granulocyte colony-stimulating factor and interferon-gamma on antifungal activity of human polymorphonuclear neutrophils against pseudohyphae of different medically important Candida species. J Leukoc Biol 1995, 57:651-656.
57. Liles WC, Huang JE, van Burik JA, Bowden RA, Dale DC. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis 1997, 175:1012-1015.
58. Kuritzkes D, Parenti D, Ward DJ, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection; results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. AIDS 1998, 12:65-74.
59. Hartung T, Pitrak DL, Foote M, Shatzen EM, Verral SC, Wendel A. Filgrastim restores interleukin-2 production in blood from patients with advanced human immunodeficiency virus infection. J Infect Dis 1998, 178:686-692.
60. Than S, Hu R, Oyaizu N, et al. Cytokine pattern in relation to disease progression in human immunodeficiency virus-infected children. J Infect Dis 1997, 175:47-56.
61. Emilie D, Flor K, Jarrousse B, et al. Cytokines in HIV infection. Int J Immunopharmacol 1994, 16:391-396.
62. Clerici M, Stocks NI, Zajak RA, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. J Clin Invest 1989, 84:1892-1899.
63. Clerici M, Shearer GM. A TH1 and TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993, 14:107-111.
64. Tomar RH. Breaking the asymptomatic phase of HIV-1 infection. J Clin Lab Anal 1994, 8:116-119.
65. Kinter A, Fauci AS. Interleukin-2 and human immunodeficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement. Immunol Res 1996, 15:1-15.
66. Stoltz DA, Bagby GJ, Nelson S. Use of granulocyte colony-stimulating factor in the treatment of acute infectious diseases. Curr Opin Hematol 1997, 4:207-212.
67. Foster PF, Mital D, Sankary HN, et al. The use of granulocyte colony-stimulating factor after liver transplantation. Transplantation 1995, 59:1557-1563.